Seegene Inc Net Assets
Seegene Inc net assets. Based on the latest financial reports, Seegene Inc (096530) has net assets worth ₩1.04 Trillion KRW (≈ $704.41 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.27 Trillion ≈ $858.01 Million USD) and total liabilities (₩226.66 Billion ≈ $153.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 096530 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.04 Trillion |
| % of Total Assets | 82.1% |
| Annual Growth Rate | 27.79% |
| 5-Year Change | -6.07% |
| 10-Year Change | 615.5% |
| Growth Volatility | 86.85 |
Net Assets of Seegene Inc (2012–2025)
Net assets of Seegene Inc from 2012 to 2025. This chart illustrates how Seegene Inc's net assets have evolved over time, based on quarterly financial data. See Seegene Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Seegene Inc (2012–2025)
The table below shows the annual net assets of Seegene Inc from 2012 to 2025. For live market cap and overall valuation, see Seegene Inc (096530) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.02 Trillion ≈ $688.40 Million |
+3.50% |
| 2024-12-31 | ₩981.48 Billion ≈ $665.13 Million |
-4.75% |
| 2023-12-31 | ₩1.03 Trillion ≈ $698.29 Million |
-10.23% |
| 2022-12-31 | ₩1.15 Trillion ≈ $777.83 Million |
+6.14% |
| 2021-12-31 | ₩1.08 Trillion ≈ $732.85 Million |
+67.58% |
| 2020-12-31 | ₩645.32 Billion ≈ $437.32 Million |
+323.02% |
| 2019-12-31 | ₩152.55 Billion ≈ $103.38 Million |
+19.15% |
| 2018-12-31 | ₩128.03 Billion ≈ $86.76 Million |
+2.39% |
| 2017-12-31 | ₩125.04 Billion ≈ $84.74 Million |
-11.93% |
| 2016-12-31 | ₩141.97 Billion ≈ $96.21 Million |
+5.09% |
| 2015-12-31 | ₩135.09 Billion ≈ $91.55 Million |
+42.45% |
| 2014-12-31 | ₩94.83 Billion ≈ $64.27 Million |
+12.30% |
| 2013-12-31 | ₩84.44 Billion ≈ $57.23 Million |
+101.36% |
| 2012-12-31 | ₩41.94 Billion ≈ $28.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Seegene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2725.8% over the analyzed period, indicating profitable operations and earnings retention.
Seegene Inc Net Assets Breakdown (December 2025)
Seegene Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.09 Trillion | 107.18% |
| Total Equity | ₩1.02 Trillion | 100.00% |
Seegene Inc Competitors by Market Cap
The table below lists competitors of Seegene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Great Shengda Packaging Co Ltd
SHG:603687
|
$966.65 Million |
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
$967.03 Million |
|
Hubei Heyuan Gas Co Ltd
SHE:002971
|
$967.33 Million |
|
Cangzhou Mingzhu Plastic Co Ltd
SHE:002108
|
$967.38 Million |
|
Quanex Building Products
NYSE:NX
|
$966.32 Million |
|
Latigo Biotherapeutics, Inc. Common Stock
NASDAQ:LTGO
|
$965.98 Million |
|
CHERVON HOLDINGS LTD
F:AZ9
|
$965.89 Million |
|
Hangjin Technology Co Ltd
SHE:000818
|
$965.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seegene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 978,626,295,130 to 1,015,447,544,130, a change of 36,821,249,000 (3.8%).
- Net income of 48,274,770,360 contributed positively to equity growth.
- Dividend payments of 36,900,802,200 reduced retained earnings.
- Share repurchases of 4,126,946,220 reduced equity.
- Other factors increased equity by 29,574,227,060.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩48.27 Billion | +4.75% |
| Dividends Paid | ₩36.90 Billion | -3.63% |
| Share Repurchases | ₩4.13 Billion | -0.41% |
| Other Changes | ₩29.57 Billion | +2.91% |
| Total Change | ₩- | 3.76% |
Book Value vs Market Value Analysis
This analysis compares Seegene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.51x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2720.46 | ₩31300.00 | x |
| 2017-12-31 | ₩2405.40 | ₩31300.00 | x |
| 2018-12-31 | ₩2462.83 | ₩31300.00 | x |
| 2019-12-31 | ₩2934.53 | ₩31300.00 | x |
| 2020-12-31 | ₩12413.77 | ₩31300.00 | x |
| 2021-12-31 | ₩20971.05 | ₩31300.00 | x |
| 2022-12-31 | ₩23036.65 | ₩31300.00 | x |
| 2023-12-31 | ₩22052.71 | ₩31300.00 | x |
| 2024-12-31 | ₩21188.30 | ₩31300.00 | x |
| 2025-12-31 | ₩22290.20 | ₩31300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seegene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.18%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.22x
- Recent ROE (4.75%) is below the historical average (16.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.65% | 14.19% | 0.47x | 1.46x | ₩-333.62 Million |
| 2015 | 5.01% | 10.40% | 0.34x | 1.44x | ₩-6.73 Billion |
| 2016 | 5.02% | 9.67% | 0.35x | 1.46x | ₩-7.07 Billion |
| 2017 | 1.59% | 2.29% | 0.53x | 1.32x | ₩-10.52 Billion |
| 2018 | 8.38% | 10.49% | 0.62x | 1.28x | ₩-2.07 Billion |
| 2019 | 17.48% | 21.87% | 0.62x | 1.28x | ₩11.42 Billion |
| 2020 | 77.83% | 44.64% | 1.03x | 1.70x | ₩437.75 Billion |
| 2021 | 49.62% | 39.14% | 0.92x | 1.38x | ₩428.42 Billion |
| 2022 | 15.87% | 21.34% | 0.61x | 1.21x | ₩67.36 Billion |
| 2023 | 0.07% | 0.18% | 0.29x | 1.22x | ₩-102.10 Billion |
| 2024 | -2.08% | -4.91% | 0.34x | 1.23x | ₩-118.20 Billion |
| 2025 | 4.75% | 10.18% | 0.38x | 1.22x | ₩-53.27 Billion |
Industry Comparison
This section compares Seegene Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $287,302,015,827
- Average return on equity (ROE) among peers: -9.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seegene Inc (096530) | ₩1.04 Trillion | 9.65% | 0.22x | $966.49 Million |
| ORIENTBIO Inc. (002630) | $62.29 Billion | 1.41% | 1.19x | $94.35 Million |
| Green Cross (005250) | $895.76 Billion | 3.06% | 4.14x | $285.63 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $82.42 Billion | -31.18% | 0.21x | $361.91 Million |
| GeneOne Life Science Inc (011000) | $24.06 Billion | -31.66% | 1.13x | $32.81 Million |
| HLB Co. Ltd (028300) | $46.46 Billion | 0.00% | 0.75x | $3.66 Billion |
| Mgenplus Co. Ltd. (032790) | $11.48 Billion | -51.58% | 1.56x | $19.35 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $43.14 Billion | 6.18% | 0.41x | $21.71 Million |
| Hyundai Bioscience Co. Ltd (048410) | $14.17 Billion | 0.00% | 1.15x | $342.04 Million |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more